Literature DB >> 15925705

Nitrosative stress and pharmacological modulation of heart failure.

Pal Pacher1, Richard Schulz, Lucas Liaudet, Csaba Szabó.   

Abstract

Dysregulation of nitric oxide (NO) and increased oxidative and nitrosative stress are implicated in the pathogenesis of heart failure. Peroxynitrite is a reactive oxidant that is produced from the reaction of nitric oxide with superoxide anion and impairs cardiovascular function through multiple mechanisms, including activation of matrix metalloproteinases (MMPs) and nuclear enzyme poly(ADP-ribose) polymerase (PARP). Recent studies suggest that the neutralization of peroxynitrite or pharmacological inhibition of MMPs and PARP are promising new approaches in the experimental therapy of various forms of myocardial injury. In this article, the role of nitrosative stress and downstream mechanisms, including activation of MMPs and PARP, in various forms of heart failure are discussed and novel emerging therapeutic strategies offered by neutralization of peroxynitrite and inhibition of MMPs and PARP in these pathophysiological conditions are reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925705      PMCID: PMC2228264          DOI: 10.1016/j.tips.2005.04.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  80 in total

1.  Leukocyte-depleted terminal blood cardioplegia provides superior myocardial protective effects in association with myocardium-derived nitric oxide and peroxynitrite production for patients undergoing prolonged aortic crossclamping for more than 120 minutes.

Authors:  Yoshitaka Hayashi; Yoshiki Sawa; Naoto Fukuyama; Yuji Miyamoto; Toshiki Takahashi; Hiroe Nakazawa; Hikaru Matsuda
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

2.  INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.

Authors:  Gábor Szabó; Pál Soós; Susanne Mandera; Ulrike Heger; Christa Flechtenmacher; Susanne Bährle; Leila Seres; Attila Cziráki; Andre Gries; Zsuszanna Zsengellér; Christian F Vahl; Siegfried Hagl; Csaba Szabó
Journal:  Shock       Date:  2004-05       Impact factor: 3.454

3.  Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass.

Authors:  Gábor Szabó; Pál Soós; Susanne Bährle; Zsuzsanna Zsengellér; Christa Flechtenmacher; Siegfried Hagl; Csaba Szabó
Journal:  Eur J Cardiothorac Surg       Date:  2004-05       Impact factor: 4.191

Review 4.  Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium.

Authors:  Deborah A Siwik; Wilson S Colucci
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

5.  Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1.

Authors:  Basilia Zingarelli; Paul W Hake; Michael O'Connor; Alvin Denenberg; Hector R Wong; Sue Kong; Bruce J Aronow
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-11       Impact factor: 4.733

6.  Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury.

Authors:  Basilia Zingarelli; Paul W Hake; Michael O'Connor; Alvin Denenberg; Sue Kong; Bruce J Aronow
Journal:  Mol Med       Date:  2003 May-Aug       Impact factor: 6.354

7.  Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity.

Authors:  Péter Bai; Jon G Mabley; Lucas Liaudet; László Virág; Csaba Szabó; Pál Pacher
Journal:  Oncol Rep       Date:  2004-02       Impact factor: 3.906

Review 8.  Poly(ADP-ribose) polymerase activation in the reperfused myocardium.

Authors:  Gábor Szabó; Lucas Liaudet; Siegfried Hagl; Csaba Szabó
Journal:  Cardiovasc Res       Date:  2004-02-15       Impact factor: 10.787

9.  Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.

Authors:  David L Brown; Kavita K Desai; Babak A Vakili; Chadi Nouneh; Hsi-Ming Lee; Lorne M Golub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-02-12       Impact factor: 8.311

Review 10.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.

Authors:  Cristine E Berry; Joshua M Hare
Journal:  J Physiol       Date:  2003-12-23       Impact factor: 5.182

View more
  79 in total

1.  Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.

Authors:  Pál Pacher; Lucas Liaudet; Jon G Mabley; Attila Cziráki; György Haskó; Csaba Szabó
Journal:  Int J Mol Med       Date:  2006-02       Impact factor: 4.101

Review 2.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 3.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 4.  Role of guanylate cyclase modulators in decompensated heart failure.

Authors:  Veselin Mitrovic; Adrian F Hernandez; Markus Meyer; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

Review 5.  Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Antigone Lazou; Anikó Görbe; Zoltán Giricz; Rainer Schulz; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

6.  Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis.

Authors:  Enkui Hao; Partha Mukhopadhyay; Zongxian Cao; Katalin Erdélyi; Eileen Holovac; Lucas Liaudet; Wen-Shin Lee; György Haskó; Raphael Mechoulam; Pál Pacher
Journal:  Mol Med       Date:  2015-01-06       Impact factor: 6.354

Review 7.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

8.  Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro.

Authors:  Partha Mukhopadhyay; Mohanraj Rajesh; Sándor Bátkai; Yoshihiro Kashiwaya; György Haskó; Lucas Liaudet; Csaba Szabó; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

Review 9.  Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.

Authors:  Zoltán V Varga; Zoltán Giricz; Lucas Liaudet; György Haskó; Peter Ferdinandy; Pál Pacher
Journal:  Biochim Biophys Acta       Date:  2014-07-02

Review 10.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.